ArticleImmunoTargets and therapy2025

PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study.

Zhaoqian He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.